Cancer News and Research

Latest Cancer News and Research

National Cancer Institute awards PDS Biotechnology $1.28M phase 2 SBIR contract

PDS Biotechnology Corporation today announced that the company has been awarded a $1.28M phase 2 SBIR contract by the National Cancer Institute division of the US National Institutes of Health. The contract provides funding to complete studies required to file an Investigational New Drug Application (IND) with the FDA for the company's lead human papillomavirus (HPV)-cancer product late in 2010.

2 Mar 2010

Rigel Pharmaceuticals reports net loss of $0.48 per share for fourth-quarter 2009

Rigel Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009.

2 Mar 2010

Supercomputer receives powerful supercomputer for biomedical and life sciences research from IBM

Rice University and IBM today unveiled a new high-performance computing initiative for biomedical and life sciences research that features one of the most powerful supercomputers in the Texas Medical Center. Rice scientists will use the supercomputer in collaboration with researchers from across the medical center to study cancer, AIDS and other complex diseases.

2 Mar 2010

ArQule reports net loss of $36,136,000 for 2009

ArQule, Inc. today announced its financial results for the year and for the fourth quarter ended December 31, 2009.

2 Mar 2010

Imaging technique combining ultrasound and microscopic bubbles help visualize tumor activity at molecular level

An imaging technique combining ultrasound and specially modified contrast agents may allow researchers to noninvasively detect cancer and show its progression, according to research published in the March issue of The Journal of Nuclear Medicine (JNM). The technique enables researchers to visualize tumor activity at the molecular level.

2 Mar 2010

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported that the U.S. Food and Drug Administration (FDA) has approved resuming clinical development of elesclomol, the Company's first-in-class oxidative stress inducer.

2 Mar 2010

Sanquin Blood Supply Foundation, Netherlands Vaccine Institute launch AmpVacs project to develop influenza A vaccine

Sanquin Blood Supply Foundation, the Netherlands Cancer Institute, and the Netherlands Vaccine Institute announce today the launch of their joint AmpVacs project aiming at the development of a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats.

2 Mar 2010

AADA: U.S. Congress fails to approve legislation preventing 21% cut in payments for physicians

The American Academy of Dermatology Association is disappointed that the United States Congress has failed to approve legislation preventing the implementation of a 21 percent cut in payments for physicians who treat Medicare patients.

2 Mar 2010

Discovery of two new compounds opens new approach to drug design against HIV protease

A team of researchers at the renowned Scripps Research Institute has discovered two new compounds that prove the existence of new binding sites on HIV protease. Associate Professor C. David Stout, senior author of the study, explained "These results open the door to a whole new approach to drug design against HIV protease," which is an enzyme used by HIV to create new, infectious viral particles.

2 Mar 2010

Children with cancer experiencing extreme pain: 13% of parents consider "hastening death"

A survey of parents who had a child die of cancer found that one in eight considered hastening their child's death, a deliberation influenced by the amount of pain the child experienced during the last month of life, report Dana-Farber Cancer Institute researchers in the March issue of Archives of Pediatrics & Adolescent Medicine.

2 Mar 2010

Future work may uncover links between insulin use and cancer risk, say researchers

The benefits of using insulin to treat diabetes far outweigh the risks, but a review just published online by IJCP, the International Journal of Clinical Practice, suggests that commonly used diabetes therapies may differ from each other when it comes to their influence on cancer risk.

2 Mar 2010

InterSystems Ensemble platform enables first successful electronic transmission of genetic data

InterSystems Corporation, the global leader in software for connected healthcare, today announced that InterSystems Ensemble® was the software platform for the first-ever successful electronic transmission of comprehensive genetic data. The information was sent cross-country from Boston-based Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) to Intermountain HealthCare in Salt Lake City, Utah. The announcement about reaching this milestone in personalized medicine came at the HIMSS10 conference.

2 Mar 2010

Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that its affiliate VGX International Inc. has received approval in Korea to begin a Phase I clinical trial in healthy volunteers for Inovio’s SynCon™ preventive DNA vaccine (VGX-3400) targeting H5N1 avian influenza.

2 Mar 2010

Consumption of garlic reduces level of potential carcinogenic processes

Researchers have designed a urine test that can simultaneously measure the extent of a potential carcinogenic process and a marker of garlic consumption in humans.

2 Mar 2010

Scientists show omega-3 fatty acid and its derivatives kill neuroblastoma cancer cells

The next treatment for cancer might come from fish says a new research report published in the March 2010 print edition of the FASEB Journal (http://www.fasebj.org). In the report, scientists show that the omega-3 fatty acid, "docosahexaenoic acid" or "DHA," and its derivatives in the body kill neuroblastoma cancer cells.

2 Mar 2010

Prevention of 21% cuts in Medicare payments to physicians: Congress fails to approve, AADA disappointed

The American Academy of Dermatology Association (AADA) is disappointed that the United States Congress has failed to approve legislation preventing the implementation of a 21 percent cut in payments for physicians who treat Medicare patients.

2 Mar 2010

UPMC, Google Health, CMU and dbMotion develop novel PHR technology

The University of Pittsburgh Medical Center (UPMC) today announced the development of personal health record (PHR) technology that may soon give patients the ability to add critical health information to the electronic health records maintained by hospitals and physicians. UPMC completed the proof-of-concept project in collaboration with Google Health, Carnegie Mellon University (CMU) and technology partner dbMotion.

2 Mar 2010

GenWay Biotech's simple blood sample cancer assessment test

San Diego-based GenWay Biotech, Inc. today announced the availability of the You Test You- Cancer Assessment that allows patients to test for various types of cancer without having to visit their doctor's office, through a simple blood sample. With a 10-day turnaround time and a cost of $149, You Test You- is a convenient and low cost way to periodically test for indication of cancer.

2 Mar 2010

ZyGEM introduces new RNAGEM Tissue RNA extraction kits

ZyGEM Corp. Ltd., a provider of innovative enzyme-based products for DNA and RNA extraction and other life sciences applications, today announced the launch of its new RNAGEM™ Tissue RNA extraction kits. This product represents a significant advance in sample preparation for RNA-based testing and analysis.

2 Mar 2010

Archimedes Pharma raises GBP65 million in new funding

Archimedes Pharma, the leading specialty pharma company, today announced that it has raised GBP65 million (approx US$100 million) in new funding. The round was led by new investor Novo Growth Equity, the growth equity fund of Novo A/S, and included participation by major current investor, Warburg Pincus, a global private equity firm. Archimedes also announced the appointment of a new President and Chief Executive Officer, Jeffrey H. Buchalter, formerly President and Chief Executive Officer of US-based Enzon.

2 Mar 2010

Cancer News and Research

Latest Cancer News and Research

National Cancer Institute awards PDS Biotechnology $1.28M phase 2 SBIR contract

Rigel Pharmaceuticals reports net loss of $0.48 per share for fourth-quarter 2009

Supercomputer receives powerful supercomputer for biomedical and life sciences research from IBM

ArQule reports net loss of $36,136,000 for 2009

Imaging technique combining ultrasound and microscopic bubbles help visualize tumor activity at molecular level

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Sanquin Blood Supply Foundation, Netherlands Vaccine Institute launch AmpVacs project to develop influenza A vaccine

AADA: U.S. Congress fails to approve legislation preventing 21% cut in payments for physicians

Discovery of two new compounds opens new approach to drug design against HIV protease

Children with cancer experiencing extreme pain: 13% of parents consider "hastening death"

Future work may uncover links between insulin use and cancer risk, say researchers

InterSystems Ensemble platform enables first successful electronic transmission of genetic data

Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial

Consumption of garlic reduces level of potential carcinogenic processes

Scientists show omega-3 fatty acid and its derivatives kill neuroblastoma cancer cells

Prevention of 21% cuts in Medicare payments to physicians: Congress fails to approve, AADA disappointed

UPMC, Google Health, CMU and dbMotion develop novel PHR technology

GenWay Biotech's simple blood sample cancer assessment test

ZyGEM introduces new RNAGEM Tissue RNA extraction kits

Archimedes Pharma raises GBP65 million in new funding

Cancer Research - Second Edition eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in